Diabetes Type 2

Risk for HF Hospitalization in Type 2 Diabetes Lower with First-line SGLT-2 Inhibitor vs Metformin
May 26, 2022

Initiating T2D treatment with an SGLT2 inhibitor reduced risk for heart failure hospitalization compared to metformin in a new study; cardiovascular outcomes were similar.

National Kidney Foundation Urges USPSTF to Prioritize Screening Recommendation for CKD
May 25, 2022

The USPSTF is rumored to have moved screening for chronic kidney disease to a preventive service it is actively considering and the NFK says, "It's time."

Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
May 25, 2022

Kosiborod, a cardiologist, and Skolnik, a family practitioner, agree no single specialty owns that prescription and that "it takes a village to care for a patient."

Metformin, Lifestyle in Prediabetes May Reduce Risk of T2D but Not Major CV Events
May 24, 2022

Among more than 3000 participants with prediabetes, neither metformin or lifestyle change reduced risk for CV events over 21 years according to Diabetes Prevention Program Outcomes Study investigators.

Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
May 23, 2022

Compare, contrast, price shop, prescribe. DiabetesWise Pro developer Korey Hood, PhD, highlights the tool all primary care clinicians should try.

Early, Consistent Glucose Control May Be Key to CVD Risk Reduction in Type 2 Diabetes: A Primary Care Analysis
May 19, 2022

In adults with type 2 diabetes seen in primary care, lowering glucose substantially during the first 12 months post-diagnosis decreased risk for future MACE.

SGLT-2 Inhibitors Belong to Patients, Not a Specialty or Primary Care: Experts Discuss
May 18, 2022

Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.

First-in-Class Tirzepatide Wins FDA Approval for Treatment of Type 2 Diabetes
May 16, 2022

Tirzepatide, a novel once-weekly GLP-1/GIP mimetic that binds to receptors and stimulates glucose-dependent insulin release, has shown superiority over many common antihyperglycemics.

Multiancestry Genetic Study of T2D Expands Potential for Risk Assessment, Treatment
May 13, 2022

A study of the most genetically diverse collection of DNA from persons with T2D yields 40 new potentially causative genes that may transcend ancestry.

Tailored Diabetes Risk Assessment May Reduce Racial/Ethnic Disparities in Diagnosis
May 11, 2022

Lowering thresholds for BMI value and age of first diabetes screening among large US minority populations could greatly increase rates of diagnosis and improve care.